CURIS INC

Curis, Inc. (NASDAQ: CURIS) is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). The company's website is www.curis.com.

Emavusertib is currently being evaluated in multiple clinical studies targeting hematologic malignancies. The TakeAim Lymphoma Phase 1/2 study (CA-4948-101) is investigating emavusertib in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL). The recently initiated TakeAim CLL study is a Phase 2 combination study evaluating emavusertib with zanubrutinib in chronic lymphocytic leukemia (CLL), with initial data expected in the fourth quarter of 2026. Monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are substantially complete. Emavusertib has received Orphan Drug Designation from the FDA for PCNSL, AML, and myelodysplastic syndrome (MDS), as well as from the European Commission for PCNSL treatment.

The company holds exclusive worldwide licenses to emavusertib through its 2015 collaboration with Aurigene Discovery Technologies Limited, covering territories except India and Russia. Under this collaboration, Curis also has licensed programs in PD1/TIM3 immune checkpoint pathways and immuno-oncology. The company previously held royalty interests in Erivedge (vismodegib), a Hedgehog signaling pathway antagonist developed by Genentech and Roche, but divested these interests in November 2025.

Curis was organized as a Delaware corporation in February 2000 and began operations in July 2000 following a merger of Creative BioMolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc. As of December 31, 2025, the company had $5.1 million in cash and cash equivalents. In January 2026, Curis completed a private placement financing for net proceeds of approximately $18.6 million. The company maintains a portfolio of 52 issued or allowed U.S. patents expiring between 2028 and 2042, with numerous pending patent applications covering compositions of matter, methods of manufacture and use, and drug screening technologies.